Abstract
AATD is a genetic disorder characterized by low levels of AAT causing emphysema, loss of lung function, and decreased survival. Plasma-derived AAT (pdAAT) therapy is approved in many countries but access ex-US remains limited due to cost/supply. Here we describe the recombinant human AAT-Fc fusion protein, INBRX-101, designed to safely achieve and maintain AAT levels within the normal range (>20 µM) using every 3 wk dosing.
This study is an open-label, international Phase 1 designed to assess safety, PK/PD, and immunogenicity of INBRX-101 (NCT03815396). AATD patients were administered single or multiple doses of 10, 40, 80 or 120 mg/kg INBRX-101 via IV infusion.
As of November 2021, 24 AATD patients have been dosed INBRX-101 at 10 mg/kg (n=6), 40 mg/kg (n=6), 80 mg/kg (n=6) and 120 mg/kg (n=6). INBRX-101 has been well tolerated without serious adverse reactions or severe drug-related adverse events. Serum antigenic PK and functional AAT levels were assessed in 21 AATD patients. Dose-dependent increases in INBRX-101 exposure were observed. Terminal half-life was 15 – 19 days. Accumulation of functional AAT levels was observed following multiple doses of 40 mg/kg or 80 mg/kg every 3 wks. Trough levels of functional AAT exceeded those achieved by current pdAAT therapies.
INBRX-101 maintains normal AAT serum levels (>20 µM) with every 3-wk dosing, with potential for longer intervals.
Footnotes
Cite this article as Eur Respir J 2022; 60: Suppl. 66, 3599.
This article was presented at the 2022 ERS International Congress, in session “-”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2022